Adamantinomatous Craniopharyngioma (ACP) is a brain tumor that afflicts both children and adults. In children, it most commonly occurs between the ages of 5 and 14 years. It has been associated with the lowest Quality of Life scores of any pediatric
brain tumor and with significantly shortened lifespan relative to otherwise healthy people.
ACP is a complex tumor to study, partially because it has both solid and cystic (fluid) components. Further, the solid components include multiple cell types, which communicate with each other to cause tumor growth and brain injury. The details of this communication are not yet understood.
Interestingly, ACP always originates in an area at the base of the brain known as the sellar/suprasellar region. ACP hurts patients by damaging nearby structures such as the hypothalamus, nerves that mediate vision, and the pituitary gland. This leads to a debilitating group of symptoms that includes cognitive dysfunction, uncontrollable obesity, vision loss, and hormonal imbalances, among others. Our laboratory studies biological and clinical features of ACP with the goal of offering new treatments for patients and families afflicted by this tumor.
For many years, therapy for ACP has included surgery with or without radiation therapy (RT). There have also been efforts to instill medications directly into the fluid components of ACP. Unfortunately, these therapies are associated with the poor quality
of outcomes that patients with ACP suffer. We need to do better. Currently, there are no medications that have been established to slow or stop ACP growth. Our lab is focused on identifying such therapies and bringing them into clinical use.
The Hankinson Lab has two primary research arms, each of which includes a high level of collaboration with colleagues on the Anschutz Medical Campus in Colorado and around the world. The first arm uses basic science methods to better understand the biology of ACP. This is highly dependent upon our collaborators from Advancing Treatment for Pediatric Craniopharyngioma, a multi-institutional North American group that shares tissue, clinical information and quality of life data regarding ACP. Using these resources, we have described gene expression characteristics of ACP and developed cultures of ACP tumor. We also collaborate closely with colleagues who have developed genetically engineered animal models and leverage other research tools to better understand ACP. Building on data from our laboratory and others, there are now initial clinical trials of new therapies for ACP underwa: https://connectconsortium.org/clinical-trials and https://pnoc.us/clinical-trial/pnoc029/.
The second arm of research conducted in the Hankinson Lab harnesses computational methods (e.g. Artificial Intelligence and Machine Learning) to pioneer research platforms to improve our understanding of ACP. Using such tools, we have published and presented
research that has improved our understanding of the genetic complexity of ACP, improved diagnostic accuracy using MRI and CT images, and identified predictable Quality of Life trajectories for ACP patients based on characteristics that are present
at diagnosis. By continuing to apply advanced computational methods, and combine them with new biological insights, we aim to develop a highly comprehensive picture of ACP, which will facilitate the delivery of highly personalized and effective therapies
against this uncommon but highly challenging disease.